Computational exploration and design of a multi-epitopes vaccine construct against Chlamydia psittaci

Amal M Alsubaiyel1, Sarah I Bukhari2

  • 1Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia.

Insights

This study designed a multi-epitope vaccine against Chlamydia psittaci using in-silico methods due to rising antibiotic resistance. The computational approach predicted a robust vaccine construct with strong binding to immune receptors, indicating potential protection against C. psittaci infections.

Area of Science:

  • Computational vaccinology
  • Infectious disease research
  • Bioinformatics

Background:

  • Chlamydia psittaci is a dangerous intracellular pathogen causing severe human infections.
  • Increasing antibiotic resistance in C. psittaci strains necessitates alternative control strategies.
  • There is currently no licensed vaccine available for C. psittaci.

Purpose of the Study:

  • To design a multi-epitope vaccine against Chlamydia psittaci using in-silico techniques.
  • To evaluate the potential immunogenicity and stability of the designed vaccine construct.

Main Methods:

  • Pan-genome analysis of 26 C. psittaci strains to identify core proteins.
  • Prediction and filtering of B-cell and T-cell epitopes based on antigenicity, solubility, and stability.
  • In-silico construction of a multi-epitope vaccine, 3D structure prediction, and docking analysis with MHC-I, MHC-II, and TLR-4 receptors.

Main Results:

  • Selected extracellular and outer membrane proteins were analyzed for epitope prediction.
  • The designed vaccine construct exhibited favorable antigenicity, stability, and adhesive properties.
  • Docking analysis showed strong binding affinity to MHC-I (-4.37 kcal/mol), MHC-II (-0.20 kcal/mol), and TLR-4 (-22.38 kcal/mol), with stable complex dynamics.

Conclusions:

  • The in-silico designed multi-epitope vaccine construct demonstrates potential for robust immune responses.
  • The computational approach provides a promising strategy for developing a protective vaccine against Chlamydia psittaci infections.